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Abstract
Background: ASPM (Abnormal Spindle-like Microcephaly associated) over-expression was recently implicated in the
development of malignant gliomas.
Results: To better characterize the involvement of ASPM in gliomas, we investigated the mRNA expression in 175
samples, including 8 WHO Grade II, 75 WHO Grade III and 92 WHO Grade IV tumors. Aspm expression was strongly
correlated with tumor grade and increased at recurrence when compared to the initial lesion, whatever the initial
grade of the primary tumor. ASPM expression also increased over serial passages in gliomaspheres in vitro and in
mouse xenografts in vivo. Lentivirus-mediated shRNA silencing of ASPM resulted in dramatic proliferation arrest and
cell death in two different gliomasphere models.
Conclusion: These data suggest that ASPM is involved in the malignant progression of gliomas, possibly through
expansion of a cancer stem cell compartment, and is an attractive therapeutic target in glioblastoma multiforme.
Introduction
Gliomas are the most common type of primary tumors
in the central nervous system (CNS), and their usual
fate is to recur, either as a similar or more frequently as
a higher grade lesion, explaining their grim prognosis.
The cellular origin of gliomas remains unknown, but
accumulating data suggest that transformed, stem-like
precursors (CSC) may represent the cells that drive their
growth [1,2].
The product of ASPM gene (Abnormal Spindle-like
Microcephaly associated) localizes to centrosomes, spin-
dle poles, and the midbody [3]. By promoting neuroblast
proliferation and driving the orientation of mitotic clea-
vage, it allows for symmetric, proliferative division of
neuroepithelial cells during brain development, and con-
sequently brain surface expansion [3]. Mutations within
this gene produce primary microcephaly [4]. In addition
to its role in embryonic development, ASPM is highly
expressed in many tumor cell lines [5], suggesting an
important involvement of this gene during tumorigen-
esis. Recent evidence suggests that ASPM is also overex-
pressed in malignant gliomas and that its knockdown
inhibits tumor proliferation [6,7].
In this study, we report that ASPM expression is cor-
related with tumor grade and increases at recurrence or
after consecutive passages in vitro and in vivo. Further-
more, we found that shRNA-mediated inhibition of
ASPM results in dramatic growth inhibition and exten-
sive cell death in gliomaspheres.
Materials and methods
Patients and tissue samples
Tumor samples frozen in liquid nitrogen were obtained
from patients who underwent surgery for a glioma at
our institution and gave informed consent for molecular
research studies. Histological diagnoses were made
according to the World Health Organization (WHO).
BAC-array-based Comparative Genomic Hybridization
analysis (CGH-array) was performed as previously
described [8]. Non-tumoral (NT) control brain (cerebel-
lum and white matter) was obtained from injured or
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epileptic patients (cryptogenetic epilepsy) who under-
went surgery.
Total RNA isolation, reverse transcription (RT) and
quantitative real-time PCR (qPCR)
Total RNA extraction was performed using RNAble blue
solution (Eurobio, France) according to the manufac-
turer’s instructions. Total RNA was systematically ana-
lyzed on both a spectrophotometer and an Agilent 2100
bioanalyzer (Agilent Technologies, FRANCE). cDNA
was prepared from 1 μg RNA using a combination of
random primers (48190-011; Invitrogen, France) and
MMLV reverse transcriptase (28025-013; Invitrogen,
France).
Gene expression was quantified by Syber Green real-
time qPCR analysis (Absolute solute Syber Green Rox
Mix, Abgene, Paris, France). Real-time qPCR cycles
were as follows: initial denaturation at 95°C for 15 min-
utes, 95°C for 30 seconds and annealing at 60°C for 1
min. Cycles were repeated 40 times. Primers were as fol-
lows: ASPM, Quantitect Primers Assay (ref:
QT00020209 Qiagen). The amount of cDNA was nor-
malized to the amount of the ALAS housekeeping gene
(Human Erythroid 5-Aminolevulinate Synthase) using
primers F: 5’-TGCAGTCCTCAGCGCAGTCT-3’ and R:
5’-TGGCCCCAACTTCCATCAT-3’. The 2-ΔΔCT equa-
tion was applied to calculate the relative copy number
of tumor samples versus non-neoplastic tissues.
Cell Isolation and culture
Briefly, tumors were immediately collected after surgery
in HBSS (14175, Invitrogen) and dissected after removal
of gross necrosis, subjected to a trypsin digestion (5 mg/
mL) for 10 min at 37°C, and then trituration and filter-
ing. The cell suspension obtained was then plated at a
density of 5.105 cells/75 cm2 flask (Corning, FRANCE)
in 10 mL of DMEM/F12 medium supplemented with
Insulin (5 mg/mL), Penicillin - Streptomycin (50 mg/
mL) and growth factor (bFGF; 20 ng/mL), epidermal
growth factor (EGF; 20 ng/mL) and B27 (1/50) as a
stem cell-permissive medium and maintained in a 5.0%
CO2/95% O2 atmosphere with 100% humidity. Cultures
were fed every three days by changing half of the med-
ium. Primary gliomaspheres were obtained after 5-10
days.
The U87 and U251 glioblastoma cell lines and the
HEK293T kidney cell line were purchased from ATCC
(American Type Culture Collection, USA), grown on
DMEM 10% FCS- 1% Penicillin-Streptomycin, and used
as controls for in vitro experiments.
LV-shRNA transduction and viability Fluorescence-
activated cell sorter analysis of Gliomaspheres
We used pGIPZ (RHS4287, Biovalley FRANCE) lenti-
viral vectors expressing a short hairpin RNA (LV-





or a scrambled non-targeted shRNA (RHS 4346; Bioval-
ley FRANCE.) as a control.
Lentiviral vector stocks were produced by transient
transfection of HEK293T cells with the p8.91 encapsida-
tion plasmid [9], the VSV glycoprotein-G-encoding
pHCMV-G plasmid [10], and the lentiviral recombinant
vector as previously described [11]. Supernatants were
treated with DNAse I (Roche Diagnostic) prior to ultra-
centrifugation, and the resulting pellet was resuspended
in Phosphate Buffered Saline, separated into aliquots
and frozen at -80°C until use. The transduction effi-
ciency of each vector stock was determined by FACS
analysis as previously described [12].
Gliomasphere cultures were mechanically disaggre-
gated in order to increase the efficiency and uniformity
of infection and then transduced at 3-5.106 cell/mL with
LV-sh-miR of ASPM and non-targeted shRNA at a mul-
tiplicity of infection of 2.5 (MOI: number of transducing
units per cell) supplemented with DEAE dextran (20 μg/
mL). After expansion of the culture, GFP-positive viable
cells were separated by cell sorting and flow cytometry
FACS (FACS Aria™ PQ1300010, BD Biosciences) to
ensure knockdown efficiency. After 7 days, ASPM RNA
expression was measured in glioma stem cells infected
with lentiviruses by real-time qPCR.
Proliferation and cell death quantification
Proliferation was assessed by EDU incorporation (Click
iT™ EdU Flow Cytometry Assay Kits, A10202 Invitro-
gen), and cell death by 7-AAD+cell staining. The per-
centage of labeled cells was quantified by cell sorting on
flow cytometry FACS (FACS Aria™ PQ1300010, BD
Biosciences).
Subcutaneous Xenograft formation assay
2 to 5 × 105 cells suspended in 100 μl of HBSS medium
were injected subcutaneously into nude mice. Before
xenograft establishment, tumors were passed four times
and genomic stability was checked by CGH array
analysis.
ASPM Immunofluorescence
To detect the endogenous ASPM protein, cultured cells
were fixed for 15 min in 4% paraformaldehyde, washed
twice in PBS, treated for 30 min with 0.1 Triton X-100 -
5% FCS, and incubated for 30 minutes at room tem-
perature with Rabbit-anti-ASPM (IHC Antibody Affinity
purified Cat IHC_00058 BETHYL, dilution 1:50) in 0.1
Triton X-100 -1% FCS. After two washes in 0.1 Triton
X-100 -1% FCS, samples were incubated for 30 minutes
at room temperature with goat anti-rabbit IgG-FITC
(dilution 1:1000) in 0.1 Triton X-100 -1% FCS. After
two washes, samples were stained with Hoechst solution
and rinsed with PBS. Samples were mounted with
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Fluoromount® (0100-01, SouthernBiotech, France).
Images were captured with a Zeiss microscope (Axio-
photo) equipped with a cooled CCD camera (Cool
SNAP HQ, Photometrics, Tucson, AZ, USA and ana-
lyzed by IPLab software).
Protein extraction and ASPM Western blot
Total protein, obtained by lysing tumor tissue or cells
with RIPA 1× buffer (SDS 20%, NP-40 20%, Deoxycho-
late acid 10%, Tris-HCl 2 M pH: 8, NaCl 5 M for 10×
buffer) was quantified using a Pierce BCA™ Protein
Assay Kit (ref 23225 Pierce, USA), separated on Nu-
Page 3-8% Tris-acetate polyacrylamide gels (Invitrogen),
and electro-transferred to nitrocellulose membranes
(Bio-Rad Laboratories, Inc.) in 25 mM Tris, 192 mM
glycine, 20% ethanol, and 0.01% SDS for 2.5 - 3 hours at
80-150 volts. After blocking in 5% milk solution, the
membranes were probed with anti- ASPM (K-17 sc-
48883) and anti- GAPDH (V-18 sc-20357) both from
Santa Cruz Biotechnology, Inc., U.S.A. Antibodies were
diluted 1:500 for ASPM and 1:700 for GAPDH in TBST
(50 mM Tris Base, 150 mM NaCl, 0.1% (v/v) Tween-20)
containing 5% milk powder. After washing in TBST, the
membrane was incubated with appropriate horseradish
peroxidase (HRP)-conjugated secondary antibodies
diluted 1:5000 in TBST. The immunoreactive signals
were detected using an ECL reagent Advance Western
Blotting Detection Kit (GE Healthcare) and an Image
Reader LAS-1000 Pro ver. 2 (KODAK PHOTO FILM
4000 mm, FRANCE).
Statistical analysis
The c2 test was used to compare qualitative variable dis-
tribution, and the Mann-Whitney test was used for con-
tinuous variables. A two-sided p-value < 0.05 was
considered to be significant.
Results
1. ASPM expression increases with glioma grade
We measured ASPM expression via qRT-PCR in 175
gliomas (8 Grade II, 75 Grade III and 92 Grade IV) and
in three non-neoplastic brain tissues (NT). ASPM expres-
sion level increased between NT tissue and Grade II glio-
mas (p < 0.05), between Grade II and Grade III (p <
0.005), and between Grade III and Grade IV (p = 0.0001).
ASPM expression did not differ between astrocytic (2
AII, 36 AIII), oligodendroglial (1 OII, 13 OIII) or mixed
glioma samples (5 OAII, 26 OA III) (Figure 1a).
Preliminary results with western blot analysis showed
that ASPM was also expressed at the protein level in
gliomas and overexpressed in Grade IV gliomas as com-
pared to Grades III and II (additional file 1, Figure S1).
2. ASPM is upregulated in recurrent gliomas relative to
the initial tumor
ASPM mRNA expression was measured in 11 recurrent
tumors and compared to the initial tumor (3 Grade II, 1
Grade III and 7 Grade IV). As shown in Figure 1b,
increased malignancy at recurrence was identified in all
4 non-glioblastoma patients with concomitant increase
of ASPM expression in all of them. In the 7 patients
whose initial tumor was a GBM (Figure 1c), ASPM
expression was 3.5-fold higher in the recurrent tumor
although the grade did not change (p < 0.005).
3. ASPM expression increases with the number of
passages in gliomaspheres and in xenografted tumors
Because ASPM expression increases with the recurrence
of glioma, and because ASPM is involved in tumor stem
cells, we investigated ASPM expression over time in
vitro in spheroid cultures and in vivo on xenografts
We generated three gliomaspheres cultures, GBM1,
GBM2, GBM3, all characterized by EGFR amplification
and 10q loss on CGH-array analysis; this genetic profile
remained stable throughout the passages (as shown in
additional file 2, Figure S2 for GBM1). We also verified
the capacity of gliomaspheres to differentiate in the pre-
sence of fetal bovine serum and to express multilineage
markers (additional file 2, Figure S2). After dissociation
of gliomaspheres, ASPM was detected during mitosis
and located at the spindle poles of dividing cells (Figure
2a). ASPM transcript expression significantly increased
throughout the passages for all gliomaspheres studied
(Figure 2b). For example, in GBM1 gliomaspheres, we
observed a 6.5-fold increase in ASPM mRNA level
between passages 8 and 28.
After four passages and after checking genomic stability
via CGH-a (not shown), 500,000 dissociated cells from
GBM1 gliomaspheres were injected subcutaneously into
immunodeficient nude mice. ASPM mRNA, measured
by RT-PCR, increased progressively with successive
tumor passages (Figure 2c).
4. ASPM silencing inhibits cell proliferation/gliomasphere
formation and promotes cell death
To determine the role of ASPM, we infected glioma-
spheres with lentivirus expressing a sh-miR-RNA that
specifically target Aspm. In GBM1, GBM2 and GBM3
gliomasphere models, ~80% of cells were successfully
transduced with the sh-miR-RNA specific to Aspm. In
transduced cells, ASPM expression measured by RT-
PCR was dramatically reduced to less than 5% in GBM2
and less than 0.02% in GBM1 and GBM3 (additional file
3, Figure S3). We then analyzed cell kinetics in three
different groups: non-transduced cells, cells transduced
with the non-targeted sh-miR-RNA, and cells trans-
duced with sh-miR-Aspm. After day 5, cells transduced
with the non-silencing sh-miR-RNA proliferated again
while the sh-miR-Aspm cells died (Figure 3a-b). The
morphology of the cells is shown at day 33 in Figure 3c
and 3d. We then quantified the effects of Aspm silen-
cing on proliferation (assessed by 5-Ethyl -2’-Deoxyuri-
dine (EdU) incorporation) and cell death (assessed by
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7-AAD+ labeling). We noted an accumulation of dead
cells in sh-miR-Aspm populations (80% of 7-AAD
+GBM1, as shown in Figure 4b, and 85% of 7-AAD+
GBM2) compared to control (Figure 4a). In addition to
cell death, ASPM inhibition resulted in a decrease in
proliferation: in sh-miR-Aspm GBM1 gliomaspheres,
only 25% of the viable cells (i.e., 5% of total cells) were
EdU+ cells (Figure 4d), compared to 64% in the non-
silenced cell population (Figure 4c). For GBM2, the
results were similar: 4% of 15% of viable cells were EDU
+ in sh-miR-Aspm GBM2 gliomaspheres vs. 81% in con-
trol GBM2 (data not shown).
5. ASPM silencing inhibited gliomasphere formation of
GBM cancer stems cells
In order to evaluate more specifically the impact of
Aspm silencing on GBM cancer stem cells, we con-
ducted a secondary gliomasphere-forming assay in
GBM1. Seven days after silencing, GFP+ cells were
Figure 1 Aspm expression correlates with glioma grade and increases at recurrence. (a) Aspm is up-regulated in gliomas compared to
non-tumor brain and increases with the tumor grade;(b) ASPM expression increases between the initial tumor and recurrence at a higher
grade; (c) ASPM expression also increases at recurrence when the initial tumor is already a Grade IV GBM. The scale bar represents the standard
error of the mean (SEM).
Bikeye et al. Cancer Cell International 2010, 10:1
http://www.cancerci.com/content/10/1/1
Page 4 of 9
Figure 2 ASPM expression in gliomaspheres increases with successive passages in vitro and in vivo. (a) Metaphase staining of ASPM
protein at both poles of the spindle. ASPM protein (green) is detected in gliomaspheres (arrow). Nuclei are stained with DAPI (blue); (b) ASPM
expression increases with successive passages (p) in gliomaspheres issued from GBM 1, 2 and 3. Passages were performed in vitro every 8 to 12
days; (c) GBM1 cells were subcutaneously engrafted into nude mice and Aspm expression was measured over four passages. Aspm expression
increased progressively in xenograft tumor (mean +/- SEM; n = 3 to 5 mice for each point. In vivo passages were performed every 8-16 weeks.
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Figure 3 ASPM knockdown in glioblastoma gliomaspheres. Cell kinetics of GBM1 (a) and GBM2 (b) gliomaspheres. The data were generated
from three independent experiments. Gliomaspheres treated with sh-miR-Aspm do not grow as compared to non-transduced gliomaspheres and
gliomaspheres transduced with non-silencing sh-miR-RNA, which start growing again after a transient drop; (c, d) at day 33, there is extensive
cell death in cell populations of GBM1 and GBM2 expressing the ASPM-silencing sh-miR-RNA as compared to the cells expressing a non-targeted
sh-miR-RNA.
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sorted and re-incubated at 1,000 cell/10 mL. We
observed a dramatic decrease in cell number in GBM1
sh-miR-Aspm compared to the non-silenced control
(1000 cells vs. 2.8.105 cells at day 9 and 500 cells vs.
3.7.106 cells at day 15). At D15, no gliomaspheres were
observed (vs. 91 gliomaspheres in the control), indicat-
ing that the knockdown of Aspm completely abrogated
the development of secondary gliomaspheres.
Discussion
This study indicates that ASPM is tightly associated with
the malignant progression of gliomas and that its knock-
down produces extensive death of glioma cells in vitro.
As previously described [7], we found that ASPM
expression was strongly correlated with the grade of
gliomas. In recurrent tumors, ASPM expression
increased not only in patients who progressed to a
higher grade, but also in recurrent glioblastomas, sug-
gesting that a progressive increase in ASPM mRNA
expression is a marker for the inexorable malignant
progression and aggressiveness of gliomas, continuing
even when the tumors have already reached their most
anaplastic histological stage (Grade IV). Experimental
evidence supports this finding since we found a progres-
sive increase in ASPM mRNA expression in serial pas-
sages of gliomaspheres in vitro and in mouse glioma
Figure 4 Cell death and proliferation inhibition induced by ASPM silencing, evaluated by 7-Actinomycin D (7-AAD) labeling and 5- Ethyl
-2’- Deoxyuridine (EdU) incorporation. Compared to control (a), transduction of GBM1 with sh-miR-Aspm results in massive cell death (b) and
a marked decrease in proliferation of surviving cells, with only 25% of the viable cells being EdU+ (d), compared to 64% for the controls (c).
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xenografts in vivo. To explain such a tight correlation
between ASPM expression and the malignant progres-
sion of tumors, an attractive hypothesis is that sym-
metric division of CSC-expressing ASPM leads to
progressive proliferative expansion of this undifferen-
tiated compartment. Although we found that ASPM
was also expressed at the protein level in all glioma
grades and overexpressed in Grade IV gliomas, it is
worth noting that the results were less striking. This
finding has been previously noted and led to the sugges-
tion that ASPM could be in part regulated at the trans-
lational level [7]. However, the dramatic inhibition of
gliomasphere proliferation obtained with shRNA-
mediated ASPM knockdown highlights the potential
importance of this gene in malignant gliomas. Sphere
formation is a key behavior of neural and brain tumor
stem cells and is used to test stem cell capacity for self-
renewal. A previous study also showed that siRNA-
mediated inhibition of ASPM resulted in cell prolifera-
tion inhibition, thought to be mediated by a G1-phase
cell cycle arrest [6]. The effect that we observed here by
stable transduction of shRNA expression in CSC-
enriched cells appears even more drastic, possibly
because of a more efficient and longer lasting inhibition
of ASPM. Whereas siRNA transfection results in a tran-
sient effect, lentiviral-mediated expression of shRNA
allows the transgene to integrate into the genome of the
host cell, resulting in long-term expression. Production
of secondary spheres was also inhibited after ASPM
knockdown, a finding compatible with a sustained inhi-
bition of CSC proliferation. Interestingly, stable inhibi-
tion of ASPM not only prevented further growth but
also produced rapid and extensive cellular apoptotic
death in our model. This finding may indicate that, fol-
lowing ASPM inhibition, CSC underwent active matura-
tion and differentiation but could not survive in our
experimental setting (serum-free medium without
appropriate growth factors). However, experiments by
Horvath et al. conducted in a similar serum-free med-
ium resulted in growth inhibition and not massive cell
death. On the other hand, the function of ASPM in
neoplastic cells, particularly gliomas, has not been com-
pletely elucidated. In particular, the links between
ASPM and key molecular alterations of malignant glio-
mas, such as EGFR amplification or mutation (EGFR-
vIII) (an almost constant feature in gliomaspheres - 80%
in our experience), remain to be investigated. Neverthe-
less, some data suggest that these alterations are closely
related. ASPM mRNA expression was increased in an
EGFRvIII-expressing U87 glioblatoma cell line as com-
pared to an isogenic U87 line, while ASPM expression
was inhibited following the addition of erlotinib (an
EGFR tyrosine kinase inhibitor) to the EGFRvIII-expres-
sing U87 line. This observation led Horvath et al to
suggest that ASPM (and genes from the same module)
is involved downstream of the mutant EGFR. Thus,
inhibition of ASPM could prove lethal by severely ham-
pering one of the key signaling pathways of
glioblastomas.
Because ASPM is absent or expressed at very low
levels in normal brain, the considerable differential
expression levels between GBM and normal parenchyma
and the extreme in vitro sensitivity of tumor cells to
ASPM knockdown support continued research to speci-
fically target ASPM from a therapeutic perspective,
focusing on in vivo studies.
Additional file 1: Figure S1 - ASPM protein expression. ASPM
western blot analysis of grade II, III and IV gliomas (n = 4 in each group).
Relative protein expression is presented as the ratio of density value for
ASPM over GAPDH signal (mean +/- SEM).
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1475-2867-10-1-
S1.PPT ]
Additional file 2: Figure S2 - Tumor spheroid characterization.
Genomic stability was examined with CGHa analysis (left = DNA profile
from initial tumor; right = DNA profile from gliomasphere at passage
p28). The chromosomes are indicated on the x axis and copy number is
on y axis. Yellow indicates the normal genomic copy number, while
green indicates a loss and red indicates a gain in copy number. As
shown here, GBM1 carries EGFR amplification and loss of chromosome
10q. After CSC isolation in stem cell-permissive medium, gliomaspheres
were differentiated in presence of fetal bovine serum and stained by
Sox2 and O4 for stemness markers and by GFAP and Tuji1 to
characterize the potential of multi lineage differentiation of GBM1.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1475-2867-10-1-
S2.PPT ]
Additional file 3: Figure S3 - Knock-down of Aspm gene. Tumor
spheroids (GBM1, GBM2, GBM3) were transfected either with non
silencing (scrambled ShRNA) or with ASPM ShRNA expressing lentivirus,
resulting in a dramatic drop of ASPM RNA in GBM1, GBM3 and to a
lesser extent GBM2.
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